policies - Mayo Clinic Laboratories
Policies Terms of Use Terms of Use Quality and Compliance Test...
Detection of (1→3)-𝝱-D-glucan as a Marker of Invasive Fungal Disease - Insights
In this month’s “Hot Topic,” Elitza Theel, Ph.D., will discuss the detection of (1→3)-β-D-glucan (BDG) in serum as a biomarker for the presence of invasive fungal infections.
Biomarker and companion diagnostic testing - Insights
Browse our suite of diagnostic, therapeutic and prognostic, quantitative and semi-quantitative immunohistochemical stains with interpretation.
Biomarker and companion diagnostic testing - Insights
Browse our suite of diagnostic, therapeutic and prognostic, quantitative and semi-quantitative immunohistochemical stains with interpretation.
Biomarker and companion diagnostic testing - Insights
Browse our suite of diagnostic, therapeutic and prognostic, quantitative and semi-quantitative immunohistochemical stains with interpretation.
Biomarker and companion diagnostic testing - Insights
Browse our suite of diagnostic, therapeutic and prognostic, quantitative and semi-quantitative immunohistochemical stains with interpretation.
Biomarker and companion diagnostic testing - Insights
Browse our suite of diagnostic, therapeutic and prognostic, quantitative and semi-quantitative immunohistochemical stains with interpretation.
Biomarker and companion diagnostic testing - Insights
Browse our suite of diagnostic, therapeutic and prognostic, quantitative and semi-quantitative immunohistochemical stains with interpretation.
Biomarker and companion diagnostic testing - Insights
Browse our suite of diagnostic, therapeutic and prognostic, quantitative and semi-quantitative immunohistochemical stains with interpretation.
New tests launched in January - Insights
In January 2023, Mayo Clinic Laboratories announced fifty-nine new tests along with numerous reference value changes, obsolete tests, and algorithm changes.